EpiBiologics Raises $107M in Series B to Advance Protein-Degrading Cancer Drug

Why It Matters

The capital infusion validates investor confidence in targeted protein degradation as a next‑generation oncology strategy and could accelerate a novel, potentially safer therapeutic class toward market.

Key Takeaways

• $107M Series B led by GV, J&J Ventures.
• EPI-326 targets mutant EGFR on tumor cells.
• Bispecific antibody directs proteins to lysosome for degradation.
• Trials to begin H1 2026 for NSCLC, head‑neck cancer.
• Platform may enable combos with TKIs and ADCs.

Pulse Analysis

Targeted protein degradation has moved from a niche research area to a burgeoning therapeutic platform, driven by the ability to eliminate disease‑causing proteins that were previously considered undruggable. EpiBiologics’ EpiTAC technology builds on this momentum by focusing on extracellular targets, using bispecific antibodies that act as molecular tags to route proteins to the cell’s lysosomal disposal system. This approach sidesteps intracellular delivery challenges and promises a higher degree of selectivity, a key differentiator in an increasingly crowded oncology market.

EPI‑326, the company’s flagship candidate, exemplifies the precision of the EpiTAC platform. By homing in on mutant forms of the epidermal growth factor receptor (EGFR) that drive aggressive cancers, the drug aims to spare normal tissue, potentially delivering a superior safety profile compared with conventional EGFR inhibitors. Early preclinical data suggest robust degradation of tumor‑associated EGFR, and the planned Phase 1 trial in 2026 will evaluate the therapy in patients with relapsed non‑small cell lung cancer and head‑and‑neck squamous cell carcinoma. Its design also facilitates combination with tyrosine‑kinase inhibitors, offering a strategy to overcome resistance mechanisms that limit current treatments.

The $107 million raise underscores the growing appetite among venture capital and corporate investors for next‑generation modalities. Participation from GV, J&J Ventures, Novartis Venture Fund and others signals confidence that protein‑degrading antibodies can translate into commercial success. As EpiBiologics expands its pipeline to include degrader‑ADC hybrids, the company positions itself at the intersection of two high‑impact trends—targeted degradation and antibody‑drug conjugates—potentially reshaping therapeutic options for a range of solid tumors. The infusion of capital will accelerate clinical development, deepen strategic partnerships, and could set a precedent for future financing of similar biotech ventures.

Deal Summary

Biotech startup EpiBiologics announced a $107 million Series B financing to push its lead protein-degrading cancer therapy, EPI-326, into clinical trials. The round was co-led by GV and Johnson & Johnson’s corporate venture arm, with participation from Novartis Venture Fund, Samsara BioCapital, Polaris Partners and other investors. The funding will support development of its EGFR-targeted bispecific antibody and further pipeline programs.